Provided herein are methods and dose packs for the monitoring of medication adherence. In one aspect, the dose pack comprises comprise a multiplicity of doses of an agent and a multiplicity of doses of a marker and be configured to isolate a pair of at least one of the multiplicity of doses of the agent and at least one of the multiplicity of doses of the marker for co-administration of the pair to the subject according to the dosing schedule. In another aspect, the method comprises obtaining a sample from the subject subsequent to the conclusion of a monitoring window and analyzing the sample for the presence or absence of a marker or a degradation product thereof.

Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.

A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.

A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof:

##STR00001##

wherein is a single or double bond, X is NCH.sub.3 or CH.sub.2, Y is null, O or N, R.sub.1 is H, OH, and R.sub.2 is null, H, C.sub.1-C.sub.8 alkyl, (C?O)-alkyl, (C?O)-aryl, (C?O)-alkyl-aryl, (C?O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of OH, NO.sub.2, NH.sub.2, NR.sub.3R.sub.4, carbonyl, alkoxyl, alkyl or OCF.sub.3, wherein R.sub.3 and R.sub.4 independently are H, alkyl, SO.sub.2CH.sub.3, (C?O)CH.sub.3 or (C?O)NH.sub.2.

A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof:

##STR00001##

wherein is a single or double bond, X is NCH.sub.3 or CH.sub.2, Y is null, O or N, R.sub.1 is H, OH, and R.sub.2 is null, H, C.sub.1-C.sub.8 alkyl, (C?O)-alkyl, (C?O)-aryl, (C?O)-alkyl-aryl, (C?O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of OH, NO.sub.2, NH.sub.2, NR.sub.3R.sub.4, carbonyl, alkoxyl, alkyl or OCF.sub.3, wherein R.sub.3 and R.sub.4 independently are H, alkyl, SO.sub.2CH.sub.3, (C?O)CH.sub.3 or (C?O)NH.sub.2.

Described herein are compositions, methods, and kits for treating hepatic encephalopathy. A composition for treating or preventing hepatic encephalopathy comprises one or more therapeutic agents and a delivery modality comprising an edible food, beverage, candy, or gum. The one or more therapeutic agents are mixed with one or more food ingredients so that the therapeutic agent is incorporated in the delivery modality.

Described herein are compositions, methods, and kits for treating hepatic encephalopathy. A composition for treating or preventing hepatic encephalopathy comprises one or more therapeutic agents and a delivery modality comprising an edible food, beverage, candy, or gum. The one or more therapeutic agents are mixed with one or more food ingredients so that the therapeutic agent is incorporated in the delivery modality.

The present disclosure relates to an anticancer use of a novel compound, i.e., 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol. The compound of the present disclosure effectively inhibits the growth of cancer cells and tumors in vitro and in a xenograft animal model. The compound of the present disclosure illustrates an anticancer activity by inhibiting a DNA binding activity of transcription factor STAT 3 in cancer cells, inducing apoptosis of cancer cells, and reducing the expression of a cell cycle regulatory protein. The compound of the present disclosure can be developed as an active ingredient of a strong anticancer drug.

Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.

Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.